In obese patients, acipimox pretreatment enhanced the GH response to GHRH plus GHRP‑6 compared with placebo pretreatment.
In plain wordsIn people with obesity, the lipid drug acipimox increased the growth hormone rise after GHRH plus GHRP‑6 compared with placebo.
- Peptide
- GHRP-6
- Outcome
- IncreaseGH AUC after GHRH plus GHRP-6 with acipimox pretreatment in obese patients
- Study
n: not reported in source
- Comparator
- Placebo pretreatment
- Outcome group
- Growth hormone and IGF-1 · Endocrine and hormones
Measurements
- GH AUC
- 1591 micrograms per L/60 min
- placebo-GHRH-GHRP-6
- GH AUC
- 2373 micrograms per L/60 min
- acipimox-GHRH-GHRP-6
Source sentences
In fact, the placebo-GHRH-GHRP-6 AUC was 1591 +/- 349, lower (P < 0.05) than that in the acipimox-GHRH-GHRP-6 test (2373 +/- 242).
2 context sentences(design, population, supporting numbers)
To ascertain whether FFA might be responsible for the GH secretory alterations of obesity, we studied spontaneous and stimulated GH secretion in 31 obese patients after FFA reduction by acipimox, a lipid-lowering drug devoid of serious side-effects.
To induce GH release, three stimuli acting through different mechanisms were used: pyridostigmine (60 mg, orally, at -60 min), GHRH (100 micrograms, iv, at 0 min), and GHRH plus GH-releasing peptide (GHRP-6; His-D-Trp-Ala-Trp-D-Phe-Lys-NH2; both at a dose of 100 micrograms, iv, at 0 min).
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.